Featured Research

from universities, journals, and other organizations

New Compound That Acts On Peripheral Receptors May Be Promising Treatment For Some Nerve Pain

Date:
August 12, 2003
Source:
NIH/National Institute On Drug Abuse
Summary:
Results of a new study in mice and rats show that a compound which acts on a specific type of cell receptor found only outside the central nervous system decreases the animals' pain responses. But the researchers caution that studies investigating the safety and efficacy of this compound in humans have yet to be done.

Results of a new study in mice and rats show that a compound which acts on a specific type of cell receptor found only outside the central nervous system decreases the animals' pain responses. But the researchers caution that studies investigating the safety and efficacy of this compound in humans have yet to be done.

The scientists hope this approach may lead to the development of pain-relief drugs that lack the debilitating central nervous system side effects limiting the effectiveness of currently available pharmaceuticals.

"Chronic pain is one of the most significant disease states affecting Americans, in terms of economic and social impacts," says Dr. Nora D. Volkow, Director of the National Institute on Drug Abuse. "And, unfortunately, therapeutic options for the treatment of chronic pain are inadequate, partly because a number of drugs that can be used to treat pain have unpleasant side effects that limit their effectiveness, and partly because some of them have the potential for addiction and abuse."

The study, funded by NIDA, part of the National Institutes of Health, will be published online the week of August 11 in the Proceedings of the National Academy of Sciences.

Dr. T. Philip Malan, Jr., of the University of Arizona, Dr. Alexandros Makriyannis, of the University of Connecticut, and their colleagues, studied the activity of a new compound called AM1241, which acts on CB2 cannabinoid receptors. "This is one of the two types of receptors on which THC, the active ingredient in marijuana, acts," Dr. Malan says. "The CB2 receptors are in peripheral sites with immune functions, while the CB1 receptors are in the central nervous system — the brain and spinal cord. The beauty of having a compound that acts on the CB2 receptors is that you can get pain relief without the central nervous system side effects of THC, such as sleepiness and anxiety."

The scientists tested the chemical on mice and rats with neuropathic pain, a complex chronic pain state resulting from nerve injury or disease. They found that this compound increased the ability of the animals to withstand chronic pain that mirrored human models of neuropathic pain.

"Although this is far from being in clinical trials in humans, any new avenue to treat pain is a very positive step," Dr. Malan says. "Almost 6 million people in the United States may experience neuropathic pain. At almost any given time, about 1 person in 4 is experiencing some type of pain and about 1 person in 8 has some type of chronic pain. Pain costs the U.S. economy $120 billion to $180 billion per year. Even though we have therapies, many people continue to experience pain despite receiving treatment. This may be partly because the side effects of many of the drugs we can use prevent patients from using the dose that provides the most intense relief."

The next step, he says, is to test this compound in animals to assess its potential toxicity. "We don't even know how it works. It may act on peripheral nerves, but CB2 receptors have not yet been found there; it may act in some way to inhibit the release of chemicals like prostaglandins from immune cells that increase sensitivity to pain; or they may cause immune system cells to release substances that block the pain response."

AM 1241 was developed by Dr. Makriyannis.

The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports more than 85 percent of the world's research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to ensure the rapid dissemination of research information and its implementation in policy and practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at http://www.drugabuse.gov.


Story Source:

The above story is based on materials provided by NIH/National Institute On Drug Abuse. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute On Drug Abuse. "New Compound That Acts On Peripheral Receptors May Be Promising Treatment For Some Nerve Pain." ScienceDaily. ScienceDaily, 12 August 2003. <www.sciencedaily.com/releases/2003/08/030812073750.htm>.
NIH/National Institute On Drug Abuse. (2003, August 12). New Compound That Acts On Peripheral Receptors May Be Promising Treatment For Some Nerve Pain. ScienceDaily. Retrieved September 30, 2014 from www.sciencedaily.com/releases/2003/08/030812073750.htm
NIH/National Institute On Drug Abuse. "New Compound That Acts On Peripheral Receptors May Be Promising Treatment For Some Nerve Pain." ScienceDaily. www.sciencedaily.com/releases/2003/08/030812073750.htm (accessed September 30, 2014).

Share This



More Health & Medicine News

Tuesday, September 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins